Drug Profile
SEL 2906
Latest Information Update: 22 Sep 1998
Price :
$50
*
At a glance
- Originator Aventis Combinatorial Technologies Center
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 22 Sep 1998 No-Development-Reported for Thrombosis in USA (Parenteral)
- 22 Sep 1998 No-Development-Reported for Thrombosis in USA (PO)
- 23 Nov 1995 Preclinical development for Thrombosis in USA (Parenteral)